01—Abstract
Summary
Summary of the 8-K filed July 7, 2026. Cited figures are marked; the original filing is the authoritative source.
On July 6, 2026, Vertex Pharmaceuticals (VRTX) signed a definitive merger agreement to acquire Crinetics Pharmaceuticals (CRNX) for $85.00a per share in cash.
The deal values Crinetics at about $10.0 billionb in equity, or $8.8 billion net of cash. Both boards unanimously approved it. Crinetics will become a wholly owned Vertex subsidiary through a reverse triangular merger.
Closing requires Crinetics stockholder approval, HSR clearance and any required foreign clearances, and is expected in Q3 2026. The deal is not subject to a financing condition. Strategically, Vertex is adding two late-stage endocrinology assets.
PALSONIFY is an oral, once-daily treatment for acromegaly, approved by the FDA and EMA and launched in the U.S. in October 2025. Atumelnant, an oral ACTH receptor antagonist, is in pivotal development for congenital adrenal hyperplasia (CAH) and has Phase 2 data in ACTH-dependent Cushing's syndrome. Vertex says the two assets have roughly $5 billionc or more in combined peak annual revenue potential.
Management expects the deal to accelerate revenue growth, become accretive to non-GAAP operating income in 2029, and modestly affect 2026 revenue and non-GAAP operating expenses, with 2026 guidance to be updated at closing. The deal is funded with cash on hand and a $4.5 billiond unsecured 364-day bridge facility from Bank of America, BofA Securities and Morgan Stanley Senior Funding, which is expected to be replaced by permanent financing. Investors should weigh the approximately $350.5 million termination fee payable by Crinetics in specified circumstances, the January 6, 2027 outside date, and the usual risks of pipeline and launch execution.
02—Key points
Key Highlights
- Vertex will acquire all outstanding Crinetics shares for $85.00 per share in cash, a roughly $10.0 billion equity value ($8.8 billion net of cash), with unanimous approval from both boards.
- The deal adds two late-stage endocrinology assets: PALSONIFY (oral once-daily acromegaly therapy, approved and launched in the U.S. in October 2025) and atumelnant (oral ACTH receptor antagonist in pivotal development for CAH).
- Management cites more than $5 billion in combined annual peak revenue potential and expects the deal to become accretive to non-GAAP operating income in 2029.
- Financing is cash on hand plus a $4.5 billion fully committed 364-day unsecured bridge facility; the merger is not conditioned on receipt of financing.
- Closing is expected in Q3 2026, subject to Crinetics stockholder approval (majority of outstanding shares), HSR and foreign regulatory clearances, and other customary conditions.
- Crinetics would owe Vertex a termination fee of $350,474,425 (about 3.5% of equity value) in specified circumstances, including a superior proposal or an adverse recommendation change; the outside date is January 6, 2027, subject to a three-month extension in certain cases.
- Vertex states the deal advances its 'five launches in five years' goal and adds a fifth pillar to its revenue base, alongside its cystic fibrosis, pain, renal and hematology franchises.
03—Questions
Frequently Asked Questions
How much is Vertex paying for Crinetics, and how will it be paid?
Vertex will pay $85.00 per share in cash, equal to about $10.0 billion in equity value or $8.8 billion net of Crinetics' cash. Vertex plans to fund the purchase with cash on hand and $4.5 billion of bridge financing, which is expected to be replaced by permanent debt financing. Stock options and RSUs are cashed out, and underwater options are cancelled for no consideration.
What are the main closing conditions and expected timing?
Closing requires Crinetics stockholder approval by a majority of outstanding shares, expiration or termination of the HSR waiting period and any required foreign clearances, no legal restraint, and accuracy of representations and performance of covenants subject to materiality standards. There is no financing condition. Vertex and Crinetics expect the deal to close in Q3 2026, and the outside date is January 6, 2027, subject to a possible three-month extension.
What assets is Vertex acquiring, and what is their commercial potential?
PALSONIFY is an oral, once-daily selective somatostatin receptor type 2 agonist for acromegaly, approved by the FDA and EMA and launched in the U.S. in October 2025, with a label covering both treatment-naïve and switch patients. Atumelnant is an oral ACTH receptor antagonist in pivotal development for adult CAH and Phase 2/3 for pediatric CAH, with Phase 2 data in ACTH-dependent Cushing's syndrome. Vertex says the two assets have about $5 billion or more in combined peak annual revenue potential, though these are company projections, not guidance.
What are the financial impacts and when do they show up?
Vertex expects the deal to accelerate revenue growth and enhance its long-term earnings profile, with the deal becoming accretive to non-GAAP operating income in 2029. Because of the Q3 2026 closing timing, the impact on 2026 revenue and non-GAAP operating expenses is expected to be modest. Vertex plans to update its 2026 guidance at closing.
What risks could prevent or delay the deal?
Risks include failure to obtain Crinetics stockholder or regulatory approvals on time, competing offers (addressed by a no-shop with a superior proposal exception), unexpected costs, integration difficulties, and litigation. The termination fee of about $350.5 million would be payable by Crinetics in specified circumstances. Crinetics' product candidates also face the usual drug development and commercialization risks, including PALSONIFY's launch trajectory and atumelnant's regulatory path.
04—Continue